Macromoltek
Computational antibody design
Y CombinatorWinter 2018ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryDeep LearningTherapeutics
What they do
Problem
Traditional antibody discovery methods struggle to generate effective antibodies for difficult or previously inaccessible biological targets, slowing drug development.
Solution
A proprietary computational de novo antibody design platform that rapidly produces accurate antibody candidates against challenging targets.
Who it's for
Biopharma companies and biotech firms developing antibody therapeutics.
Founders
Monica Berrondo
Founder/CEO
Monica Berrondo, Ph.D., is an entrepreneur, scientist, and software engineer. Her expertise lies in antibody structure-prediction and analysis, protein functional analysis, protein mutational analysis, and computational approaches to complex scientific problems.
Susana Kaufmann
Founder/CTO
Company timeline
- Founded2010
- YC batchWinter 2018
- StatusActive
- Team size14 people
- LocationAustin, TX, USA
Similar startups
Menten AI
Menten AI designs peptide and protein therapeutics using quantum…
Forcyte Biotechnologies
Discover drugs that control how much cells "squeeze" to treat disease
Algen Biotechnologies
Using CRISPR to find treatments for cancer and inflammation
Rezo Therapeutics
Mapping PPI networks and PPI interfaces at high resolution to develop…
Parallel Bio
Using the immune system to cure disease
Ditto Biosciences
Evolutionary intelligence for autoimmune disease